NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway

Cancer Letters

Volumn 376, Issue 1, 2016, Pages 10-21

  Peng, Yun yun ^a,b   He, Ying hua ^a   Chen, Chen ^a   Xu, Tao ^a   Li, Lin ^a   Ni, Ming ming ^a   Meng, Xiao ming ^a   Huang, Cheng ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Haimen People's Hospital   (China)

Author keywords

HCC; NLRC5; Therapeutic; Wnt catenin signaling pathway; catenin

Indexed keywords

BETA CATENIN; CASPASE; CYCLIN D1; METALLOPROTEINASE; MYC PROTEIN; NLRC5 PROTEIN; RNA; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, HUMAN; NLRC5 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; MTT ASSAY; NONHUMAN; NUCLEOTIDE BINDING SITE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; UPREGULATION; WNT SIGNALING PATHWAY; WOUND HEALING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CYCLE CHECKPOINT; CELL MOTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; TIME FACTOR; TUMOR INVASION; TUMOR VOLUME; XENOGRAFT;

ADULT; ANIMALS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HETEROGRAFTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84962128693     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.03.006     Document Type: Article

References (48)

1. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
2. Yang L.Y., Fang F., Ou D.P., Wu W., Zeng Z.J., Wu F. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann. Surg 2009, 249:118-123.
3. Marrero C.R., Marrero J.A. Viral hepatitis and hepatocellular carcinoma. Arch. Med. Res 2007, 38:612-620.
4. Hoshida Y., Toffanin S., Lachenmayer A., Villanueva A., Minguez B., Llovet J.M. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin. Liver Dis 2010, 30:35-51.
5. Nhieu J.T., Renard C.A., Wei Y., Cherqui D., Zafrani E.S., Buendia M.A. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am. J. Pathol 1999, 155:703-710.
6. Donnellan R., Chetty R. Cyclin D1 and human neoplasia. Mol. Pathol 1998, 51:1-7.
7. Prins J., De Vries E.G., Mulder N.H. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res 1993, 13:1373-1385.
8. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:5522-5527.
9. Fritz J.H., Ferrero R.L., Philpott D.J., Girardin S.E. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol 2006, 7:1250-1257.
10. Benko S., Magalhaes J.G., Philpott D.J., Girardin S.E. NLRC5 limits the activation of inflammatory pathways. J. Immunol 2010, 185:1681-1691.
11. Cui J., Zhu L., Xia X., Wang H.Y., Legras X., Hong J., et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010, 141:483-496.
12. Kuenzel S., Till A., Winkler M., Hasler R., Lipinski S., Jung S., et al. The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J. Immunol 2010, 184:1990-2000.
13. Meissner T.B., Li A., Biswas A., Lee K.H., Liu Y.J., Bayir E., et al. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13794-13799.
14. Kanneganti T.D., Lamkanfi M., Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007, 27:549-559.
15. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat. Immunol 2012, 13:333-342.
16. Fernandes R., Tsuda C., Perumalsamy A.L., Naranian T., Chong J., Acton B.M., et al. NLRP5 mediates mitochondrial function in mouse oocytes and embryos. Biol. Reprod 2012, 86:138. 1-10.
17. Murdoch S., Djuric U., Mazhar B., Seoud M., Khan R., Kuick R., et al. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat. Genet 2006, 38:300-302.
18. Tong Z.B., Gold L., Pfeifer K.E., Dorward H., Lee E., Bondy C.A., et al. Mater, a maternal effect gene required for early embryonic development in mice. Nat. Genet 2000, 26:267-268.
19. Burdette D., Haskett A., Presser L., McRae S., Iqbal J., Waris G. Hepatitis C virus activates interleukin-1beta via caspase-1-inflammasome complex. J. Gen. Virol 2012, 93:235-246.
20. da Silva Correia J., Miranda Y., Austin-Brown N., Hsu J., Mathison J., Xiang R., et al. Nod1-dependent control of tumor growth. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1840-1845.
21. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
22. Ohno S., Kinoshita T., Ohno Y., Minamoto T., Suzuki N., Inoue M., et al. Expression of NLRP7 (PYPAF3, NALP7) protein in endometrial cancer tissues. Anticancer Res 2008, 28:2493-2497.
23. Villani A.C., Lemire M., Fortin G., Louis E., Silverberg M.S., Collette C., et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet 2009, 41:71-76.
24. Zaki M.H., Vogel P., Malireddi R.K., Body-Malapel M., Anand P.K., Bertin J., et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011, 20:649-660.
25. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8847-8851.
26. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8:387-398.
27. Imbeaud S., Ladeiro Y., Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin. Liver Dis 2010, 30:75-86.
28. Matsuzaki K., Murata M., Yoshida K., Sekimoto G., Uemura Y., Sakaida N., et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007, 46:48-57.
29. Sanz-Cameno P., Trapero-Marugan M., Chaparro M., Jones E.A., Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010, 2010:272170.
30. Allen I.C., TeKippe E.M., Woodford R.M., Uronis J.M., Holl E.K., Rogers A.B., et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med 2010, 207:1045-1056.
31. Hu B., Elinav E., Huber S., Booth C.J., Strowig T., Jin C., et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21635-21640.
32. Hu B., Elinav E., Huber S., Strowig T., Hao L., Hafemann A., et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9862-9867.
33. Inoue Y., Shirasuna K., Kimura H., Usui F., Kawashima A., Karasawa T., et al. NLRP3 regulates neutrophil functions and contributes to hepatic ischemia-reperfusion injury independently of inflammasomes. J. Immunol 2014, 192:4342-4351.
34. Jin L., Yuan R.Q., Fuchs A., Yao Y., Joseph A., Schwall R., et al. Expression of interleukin-1beta in human breast carcinoma. Cancer 1997, 80:421-434.
35. Negash A.A., Ramos H.J., Crochet N., Lau D.T., Doehle B., Papic N., et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013, 9:e1003330.
36. Zaki M.H., Lamkanfi M., Kanneganti T.D. Inflammasomes and intestinal tumorigenesis. Drug Discov. Today Dis. Mech 2011, 8:e71-e78.
37. Capece D., Fischietti M., Verzella D., Gaggiano A., Cicciarelli G., Tessitore A., et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res. Int 2013, 2013:187204.
38. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med 2008, 14:109-119.
39. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J. Hepatol 2008, 48:380-381.
40. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
41. Davis B.K., Roberts R.A., Huang M.T., Willingham S.B., Conti B.J., Brickey W.J., et al. Cutting edge: NLRC5-dependent activation of the inflammasome. J. Immunol 2011, 186:1333-1337.
42. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
43. Park W.S., Oh R.R., Park J.Y., Lee S.H., Shin M.S., Kim Y.S., et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999, 59:4257-4260.
44. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
45. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
46. Gao Z.H., Tretiakova M.S., Liu W.H., Gong C., Farris P.D., Hart J. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Modern Pathol 2006, 19:533-540.
47. Ochiai H., Nakanishi Y., Fukasawa Y., Sato Y., Yoshimura K., Moriya Y., et al. A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology 2008, 75:32-41.
48. Oshima T., Akaike M., Yoshihara K., Shiozawa M., Yamamoto N., Sato T., et al. Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol. Rep 2008, 20:359-364.